SAB Biotherapeutics, Inc.
SABS
$3.94
-$0.21-5.06%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -137.10% | 549.32% | -94.63% | 54.39% | -10.10% |
| Total Depreciation and Amortization | -0.29% | -1.16% | -0.49% | -0.94% | -18.74% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 110.47% | -4,988.77% | 128.03% | -250.06% | 197.81% |
| Change in Net Operating Assets | -550.60% | 72.22% | -11.43% | 156.49% | -189.89% |
| Cash from Operations | -28.55% | -82.48% | 8.28% | 18.20% | -51.50% |
| Capital Expenditure | -- | -- | -- | -- | 44.77% |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 99.40% | -2,598.54% | 11.29% | -50.24% | 991.96% |
| Cash from Investing | 98.69% | -2,598.54% | 11.28% | -49.94% | 909.54% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.94% | 79.29% | -1.11% | 37.29% | 57.77% |
| Issuance of Common Stock | -100.00% | -- | -- | -- | -- |
| Repurchase of Common Stock | 12.24% | -- | 100.00% | 91.57% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | -100.02% | 97,159.26% | 0.11% | -180.18% | 132.19% |
| Foreign Exchange rate Adjustments | -961.07% | -120.90% | 322.12% | 114.72% | -707.79% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -173.53% | 1,420.83% | 40.20% | -1,092.39% | 96.62% |